[1] FU J N, WU H. Structural mechanisms of NLRP3 inflammasome assembly and activation[J]. Annu Rev Immunol, 2023, 41:301-316.
[2] 邓波, 霍亚南. NLRP3炎症小体与代谢性疾病关系研究进展[J]. 中国当代医药, 2023, 30(17):24-27. doi:  10.3969/j.issn.1674-4721.2023.17.007
[3] MANGAN M S J, OLHAVA E J, ROUSH W R, et al. Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov, 2018, 17(8):588-606.
[4] KELLEY N, JELTEMA D, DUAN Y H, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation[J]. Int J Mol Sci, 2019, 20(13):3328.
[5] BLEVINS H M, XU Y M, BIBY S, et al. The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases[J]. Front Aging Neurosci, 2022, 14:879021.
[6] MA Q. Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction[J]. Pharmacol Rev, 2023, 75(3):487-520. doi:  10.1124/pharmrev.122.000629
[7] ZAHID A, LI B F, KOMBE A J K, et al. Pharmacological inhibitors of the NLRP3 inflammasome[J]. Front Immunol, 2019, 10:2538.
[8] YANG Y, WANG H N, KOUADIR M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors[J]. Cell Death Dis, 2019, 10(2):128. doi:  10.1038/s41419-019-1413-8
[9] DE BENEDETTI F, GATTORNO M, ANTON J, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes[J]. N Engl J Med, 2018, 378(20):1908-1919. doi:  10.1056/NEJMoa1706314
[10] LI H, GUAN Y L, LIANG B, et al. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome[J]. Eur J Pharmacol, 2022, 928:175091.
[11] BAKHSHI S, SHAMSI S. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: latest evidence and therapeutic outcomes[J]. Int Immunopharmacol, 2022, 106:108595. doi:  10.1016/j.intimp.2022.108595
[12] DAI Z, CHEN X Y, AN L Y, et al. Development of novel tetrahydroquinoline inhibitors of NLRP3 inflammasome for potential treatment of DSS-induced mouse colitis[J]. J Med Chem, 2021, 64(1):871-889. doi:  10.1021/acs.jmedchem.0c01924
[13] WANG L, ZHAO X Q, DING J W, et al. Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice[J]. Inflammopharmacology, 2023, 31(4):1993-2005. doi:  10.1007/s10787-023-01161-9
[14] HE H B, JIANG H, CHEN Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity[J]. Nat Commun, 2018, 9(1):2550.
[15] 徐博, 王茂楠. 冬凌草甲素对DSS诱导的小鼠溃疡性结肠炎的保护作用[J]. 吉林医学, 2023, 44(5):1148-1151. doi:  10.3969/j.issn.1004-0412.2023.05.002
[16] BELLOTTI P, ROGGE T, PAULUS F, et al. Visible-light photocatalyzed peri-(3 + 2)cycloadditions of quinolines[J]. J Am Chem Soc, 2022, 144(34):15662-15671.
[17] LI M, WANG C H, YE S, et al. Discovery of novel oridonin sulfamide derivatives as potent NLRP3 inhibitors by a visible-light photocatalysis-enabled peripheral editing[J]. Bioorg Med Chem Lett, 2024, 99:129621.